TY - JOUR
T1 - Associations between aflatoxin B1-albumin adduct levels with metabolic conditions in Guatemala
T2 - A cross-sectional study
AU - Alvarez, Christian S.
AU - Rivera-Andrade, Alvaro
AU - Kroker-Lobos, María F.
AU - Florio, Andrea A.
AU - Smith, Joshua W.
AU - Egner, Patricia
AU - Freedman, Neal D.
AU - Lazo-Elizondo, Mariana
AU - Guallar, Eliseo
AU - Dean, Michael
AU - Graubard, Barry I.
AU - Ramírez-Zea, Manuel
AU - McGlynn, Katherine A.
AU - Groopman, John D.
N1 - Publisher Copyright:
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
PY - 2022/1
Y1 - 2022/1
N2 - Background and Aims: Metabolic conditions such as obesity, type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD) are highly prevalent in Guatemala and increase the risk for a number of disorders, including hepatocellular carcinoma (HCC). Aflatoxin B1 (AFB1) levels are also notably elevated in the population and are known to be associated with HCC risk. Whether AFB1 also contributes to the high prevalence of the metabolic disorders has not been previously examined. Therefore, the purpose of this study was to assess the association between AFB1 and the metabolic conditions. Methods: Four-hundred twenty-three individuals were included in the study, in which AFB1-albumin adduct levels were measured in sera. Metabolic conditions included diabetes, obesity, central obesity, metabolic syndrome, and NAFLD. Crude and adjusted prevalence odds ratios (PORs) and 95% confidence intervals (95% CI) were estimated for the associations between the metabolic conditions and AFB1-albumin adduct levels categorized into quartiles. Results: The study found a significant association between AFB1-albumin adduct levels and diabetes (Q4 vs Q1 POR = 3.74, 95%CI: 1.71-8.19; P-trend.003). No associations were observed between AFB1-albumin adduct levels and the other conditions. Conclusions: As diabetes is the metabolic condition most consistently linked to HCC, the possible association between AFB1 exposure and diabetes may be of public health importance. Further studies are warranted to replicate the findings and examine potential mechanisms.
AB - Background and Aims: Metabolic conditions such as obesity, type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD) are highly prevalent in Guatemala and increase the risk for a number of disorders, including hepatocellular carcinoma (HCC). Aflatoxin B1 (AFB1) levels are also notably elevated in the population and are known to be associated with HCC risk. Whether AFB1 also contributes to the high prevalence of the metabolic disorders has not been previously examined. Therefore, the purpose of this study was to assess the association between AFB1 and the metabolic conditions. Methods: Four-hundred twenty-three individuals were included in the study, in which AFB1-albumin adduct levels were measured in sera. Metabolic conditions included diabetes, obesity, central obesity, metabolic syndrome, and NAFLD. Crude and adjusted prevalence odds ratios (PORs) and 95% confidence intervals (95% CI) were estimated for the associations between the metabolic conditions and AFB1-albumin adduct levels categorized into quartiles. Results: The study found a significant association between AFB1-albumin adduct levels and diabetes (Q4 vs Q1 POR = 3.74, 95%CI: 1.71-8.19; P-trend.003). No associations were observed between AFB1-albumin adduct levels and the other conditions. Conclusions: As diabetes is the metabolic condition most consistently linked to HCC, the possible association between AFB1 exposure and diabetes may be of public health importance. Further studies are warranted to replicate the findings and examine potential mechanisms.
KW - Guatemala
KW - NAFLD
KW - aflatoxin
KW - diabetes
KW - metabolic syndrome
KW - obesity
UR - http://www.scopus.com/inward/record.url?scp=85124379083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124379083&partnerID=8YFLogxK
U2 - 10.1002/hsr2.495
DO - 10.1002/hsr2.495
M3 - Article
C2 - 35229049
AN - SCOPUS:85124379083
SN - 2398-8835
VL - 5
JO - Health Science Reports
JF - Health Science Reports
IS - 1
M1 - e495
ER -